Targeting pathogenic Acanthamoeba castellanii using DNA minor groove binding agents.

Area of Science:

• Medicinal Chemistry
• Parasitology
• Molecular Biology

Background:

• DNA minor groove binders are sequence-specific agents with diverse biological activities.
• The DNA minor groove is a key target for therapeutic interventions due to its role in non-covalent interactions.
• Pathogenic Acanthamoeba castellanii infections pose a significant health challenge.

Purpose of the Study:

• To synthesize novel DNA minor groove binding agents.
• To evaluate the antiparasitic efficacy of these agents against Acanthamoeba castellanii.
• To assess their potential to inhibit parasite-mediated host cell damage and phenotypic switching.

Main Methods:

• Synthesis of five novel DNA minor groove binding agents.
• In vitro amoebicidal assays against Acanthamoeba castellanii (T4 genotype).
• Cytopathogenicity assays measuring lactate dehydrogenase release.
• Cytotoxicity assays on human cells.
• Phenotypic transformation assays.

Main Results:

• All synthesized agents demonstrated significant amoebicidal activity (P < 0.05).
• Pre-treatment with agents inhibited parasite-induced human cell death.
• Agents exhibited minimal cytotoxicity to human cells.
• Inhibitors effectively blocked amoebae phenotypic switching, a factor in infection recurrence.

Conclusions:

• Novel DNA minor groove binders possess significant antiparasitic properties against Acanthamoeba castellanii.
• These compounds offer a dual therapeutic approach by directly killing parasites and preventing host cell damage.
• The ability to inhibit phenotypic switching presents a novel strategy to combat infection recurrence.
• DNA minor groove binders represent a promising class of therapeutics for eradicating pathogenic Acanthamoeba infections.